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ABSTRACT
Introduction. Recent studies have shown an increase in post-
operative orthopaedic complications associated with pre-operative 
opioid use. It is, therefore, important to know if patients use opioids 
before scheduled surgery. The purpose of this study was to deter-
mine if urine drug screening (UDS) is an effective screening tool for 
detecting opioid and illicit drug use prior to joint arthroplasty (JA) 
procedures.
Methods.xThis retrospective chart review was performed with IRB 
approval on 166 out of 172 consecutive patients in a community-
based practice. All the patients had a pre-operative UDS prior to 
primary or revision JA by a fellowship trained orthopaedic surgeon 
between March 2016 and April 2017. Patient demographics docu-
mented opioid and illicit drug use, co-morbid diagnosis, and UDS 
results were collected from clinical charts. Statistical analysis was 
conducted using Pearson Chi-square, Fisher’s exact, McNemar test, 
and t-tests with IBM SPSS Statistics, ver. 23. Significant differences 
were p < 0.05. 
Results. Sixty-four of 166 patients (38.6%) tested positive for 
opioids. Among them, 55.0% (35/64) had no history of prescription 
opioid use. Significant differences were observed when comparing 
the test results of the UDS with the patient reported history of pre-
scribed opioids (p = 0.001). 
Conclusion. With a significant number of patients testing positive 
for opioids without evidence of a previous prescription, UDS may 
be beneficial for initial risk assessment for patients undergoing JA 
procedures. Kans J Med 2020;13:71-76
INTRODUCTION
Alarming increases have occurred in the rate of drug overdose 
deaths involving synthetic opioids, such as tramadol, fentanyl, and 
its analogs. Data from the National Vital Statistics System (NVSS) 
reported that the age-adjusted rate of drug overdose has increased 
88% per year from 2013 to 2016, and rose another 9.6% in 2017.1 
This report also showed that trends for natural and semisynthetic 
opioids, such as oxycodone and hydrocodone, also have increased 
steadily. Similarly, the 2016 National Survey on Drug Use and Health 
(NSDUH) estimated 28.6 million Americans aged 12 years or older 
were current illicit drug users.2 These drugs included marijuana, 
cocaine (including crack), heroin, hallucinogens, inhalants, meth-
amphetamines, and the misuse of prescription pain relievers such 
as tranquilizers, stimulants, and sedatives that were prescribed to 
someone else. 
Prescription Opioid Use. A driver of this misuse is an over-
whelming increase in physicians prescribing a long-term course of 
pain relievers, such as opioids, for chronic pain.3,4 One such condition 
is degenerative joint disease, or osteoarthritis, which is the leading 
cause of chronic pain and physical disability in older populations.5 
Opioids, which are powerful pain-relieving substances, often are pre-
scribed to patients with joint disease. Evidence indeed supports the 
effectiveness of opioids, showing an average 3-point decrease in pain 
as measured by a 10-point pain rating scale.5 
However, studies have suggested an increase in post-operative 
orthopaedic complications associated with pre-operative opioid 
use.6-11 Pre-operative drug users are at risk for longer hospital stays, 
have higher mortality rates, and more surgical complications, includ-
ing postoperative infection, anemia, convulsions, osteomyelitis, and 
blood transfusion.12 More specifically, pre-operative opioid users 
have less favorable outcomes following total knee (TKA) and total 
hip arthroplasty (THA),3,13-17 besides the fact that they require more 
opioid refills, remain on opioids longer after surgery, and have an 
increased risk of chronic opioid use postoperatively.18-20 Evidence of 
common characteristics of those who use opioids include patients 
aged 35 to 49 years, taking five or more other medications, insured 
by Medicare or Medicaid, established versus new patients, treated by 
primary care versus specialty physicians, and in prescribing regions 
of the south or west.21 
In recognition of this misuse, state-level prescription drug moni-
toring programs have been implemented in most states. Research 
to evaluate the effectiveness of these programs have been difficult 
because they vary by design and requirements. One study analyzed 
physician-reported data on prescribing opioids and found that these 
programs appeared to be unsuccessful when trying to reduce physi-
cians prescribing opioids.22 It has been estimated that opioids are 
prescribed in 1 of 5 patients with non-cancer pain or pain-related 
diagnoses in an office-based setting.23 This wide spread prescribing 
practice predisposes patients to chronic drug misuse and overdose 
related deaths.8,24 
Illicit Drug Use. Seemingly, stricter enforcement of the prescrip-
tion drug monitoring programs is merited and could lead to reduced 
drug misuse. However, this may lead to another issue in appropri-
ate pain management: increased illicit drug use.25 Indeed, recent 
literature showed an increase in complications in the trauma popu-
lation associated with illicit drug use.26 With ever increasing access 
to and use of illicit drugs in the United States,24 rates of drug misuse 
necessitates awareness and surveillance by all physicians. In elective 
orthopaedic procedures where the underlying goal is to improve the 
quality of the patient’s life, it is important for orthopaedic physicians 
to have a thorough risk assessment of the patient to determine the 
most appropriate treatment course for his/her diagnosis. An accu-
rate and up-to-date history and physical examination may be the best 
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negative perceptions of opioid and illicit drug use, patients may be 
reluctant to disclose this information to the physician. 
Study Objective. To evaluate the extent to which patients disclose 
opioid and illicit drug use, we conducted urine drug screening (UDS) 
in our clinic for all patients who were scheduled for joint arthroplas-
ty (JA). Our primary objective was to minimize complications and 
readmissions following JA in high-risk patients. The purpose of this 
study was to compare self-reported pre-operative drug use with UDS 
test results to determine if UDS would be an effective screening tool 
for detecting opioid and illicit drug use. We hypothesized that there 
would be a significantly high number of individuals in the JA popula-
tion who do not reveal pre-operative drug use prior to surgery, thus 
putting themselves at undo risk of postoperative complications. 
METHODS
Participants. A cross-sectional, retrospective chart review was 
performed on 172 consecutive patients in a community-based prac-
tice. Adult patients who had a pre-operative UDS prior to primary or 
revision JA were eligible to participate. Included in the subjects were 
patients scheduled for a JA between March 2016 and April 2017 by 
an adult reconstructive fellowship trained orthopaedic surgeon. JA 
was defined as primary or revision total hip arthroplasty (THA), total 
knee arthroplasty (TKA), patella femoral joint arthroplasty (PFJ), or 
uni-compartment knee arthroplasty (UKA). 
This study was approved by the institutional review board (IRB). 
Each patient was told during the evaluation in the clinic to have a 
urine test for opioids and other associated illicit drugs prior to 
scheduling of the surgery. All patients used a private restroom with a 
member of the work staff outside the door in the senior author’s clinic 
to collect their sample for the UDS. The UDS company used in this 
study was “Tru-Fit”. All screens initially were examined by a strip in 
the clinic office, then confirmed off-site by the company using a gas 
chromatography. The UDS test cost the patient approximately sixty 
dollars, however, this varied with the type of insurance. At the time of 
presentation in clinic, the intake form that documented the patient’s 
current prescribed drugs was initiated by the patient, then reviewed 
by a medical assistant with the patient to confirm the accuracy. 
Measurements. Patient information was extracted from the 
charts, which included age, gender, body mass index (BMI), primary 
diagnosis, co-morbid diagnoses (including psychiatric disorders), 
smoking status, surgical date, history of medication list, type of 
insurance (Medicare, private, or workers’ compensation), and JA 
procedure type. Data on comorbidities included diabetes, hyperten-
sion, hyperlipidemia, renal disease, major depression disorder, and 
general anxiety disorder. Pre-operative prescribed opioid use and 
UDS results also were collected. 
Outcomes. The primary outcomes were the dichotomous UDS test 
result from four drug panels. The opiate/opioid drug panel included 
tests for 6-monoacetayl morphine, buprenorphine, codeine, EDDP, 
fentanyl, hydrocodone, hydromorphone, meperidine, methadone, 
morphine, naloxone, naltrexone, norbuprenorphine, norfentanyl, 
O-Desmethyl tramadol, oxycodone, oxymorphone, tapentadol, 
and tramadol. The remaining drug panels were categorized as illicit 
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drugs that included the amphetamine panel (amphetamine, MDA, 
MDEA, MDMA, methamphetamine, methylphenidate, and phen-
termine), the cannabinoid panel (THC, J-122_4-HYDROXYL and 
JWH-200), and the “other drug” panel (benzoylecgonine, dextro-
methorphan, mitragynine, PCP, and propoxyphene). For secondary 
outcomes, patients’ pre-operative prescription medicine list was 
evaluated to determine if they were taking any pre-operative opioids. 
The number of patients taking pre-operative opioids was analyzed 
and compared to the patients that tested positive on UDS. 
To eliminate false-positive results, the senior author offered a 
second drug screen to patients who tested positive for illicit drugs 
prior to cancelling their surgery. 
Statistical Analyses. Data analysis was performed to deter-
mine the number of patients who had a positive urine toxicology for 
pre-operative opioid use or for illicit drugs, along with the number 
of patients who initially did not reveal the pre-operative drug use. 
Descriptive statistics included frequencies and percentages for cat-
egorical data. Continuous data were evaluated for normality and 
subsequently summarized with means and standard deviations. 
Groups were compared by positive or negative UDS results using 
the following two-tailed tests: Pearson Chi-square asymptotic and 
exact tests, McNemar test, and t-tests. Significant results were identi-
fied as those with p < 0.05. Analyses were conducted with IBM SPSS 
Statistics, ver. 23.
RESULTS
The analysis included 166 of the 172 patients; six patients were 
excluded because they underwent a procedure other than a JA. Data 
were missing on six participants for BMI, smoking, and insurance; 
two participants had missing data for comorbidities. The sample 
included 95 (57.2%) females and 71 (42.8%) males. The mean age 
was 64.5 years, with a standard deviation of 10.9 years. Many of the 
patients (61.9%; 99/160) were obese. Of the 166 patients screened 
with UDS, 64 (38.6%) tested positive for opiate/opioids. Regarding 
the illicit drug panels, 7 (4.2%) tested positive for Amphetamines, 6 
(3.6%) for Cannabinoids, and 2 (1.2%) for other drugs (one partici-
pant tested positive for multiple drug panels within this category).
Table 1 summarizes participant characteristics by positive UDS 
results. Two participant characteristics significantly differed by 
UDS: over 44% (41/92) of current/former smokers tested positive 
for opiate/opioids (p = 0.036), while almost 55% (18/33) diabetic 
patients tested positive (p = 0.033). No other patient factors differed 
significantly by UDS results including sex, age, BMI, insurance type, 
type of scheduled arthroplasty, or other comorbidities. However, 
almost 40% of patients (34/92) scheduled for total knee arthroplas-
ty tested positive for opiate/opioids; similarly, almost 44% (21/48) 
scheduled for total hip arthroplasty tested positive. (Note: because 
few patients tested positive for the three illicit drug panels, no other 
statistical tests were conducted for these drugs with only frequencies 
reported for these drug classes.)
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Table 1. Participant characteristics by urine drug screen results.
Positive Urine Drug Screen
Opiate/Opioid All Other
Characteristics N (%) N % p N % p
Female 95 (57.2) 37 57.8 0.904 9 64.3 0.577
Male 71 (42.8) 27 42.2 5 35.7
Mean age (SD) 166 (100.0) 63.5 (11.8) 0.342 59.6 (10.9) 0.081
BMI 0.991 0.389
Normal 15 (9.4) 6 9.7 1 7.1
Overweight 46 (28.7) 18 29.0 2 14.3
Obese 99 (61.9) 38 61.3 11 78.6
Smoking status 0.036 0.213
Current 31 (19.4) 18 29.0 3 21.4
Former 61 (38.1) 23 37.1 8 57.1
Never 68 (42.5) 21 33.9 3 21.4
Insurance type 0.982 0.314
Medicare/Medicaid 89 (55.6) 34 55.7 6 42.9
Commercial 71 (44.4) 27 44.3 8 57.1
Type of arthroplasty 0.536* 0.186*
Total knee: primary 92 (55.4) 34 53.1 6 42.9
Total hip: primary 48 (28.9) 21 32.8 3 21.4
Patella femoral joint 11 (6.6) 3 4.7 2 14.3
Total knee: revision 9 (5.4) 4 6.3 2 14.3
Total hip: revision 3 (1.8) 2 3.1 1 7.1
Uni-compartment 
knee 3 (1.8) 0 0.0 0 0.0
Co-morbidities (choose all that apply)**
Hypertension 98 (59.8) 39 61.9 0.658 7 50.0 0.436
Diabetes 33 (20.1) 18 28.6 0.033 3 21.4 0.899
Thyroid Disease 28 (17.1) 14 22.2 0.166 1 7.1 0.302
Heart Disease 27 (16.5) 10 15.9 0.872 1 7.1 0.325
PMH of Cancer 29 (17.7) 7 11.1 0.081 0 0.0 0.070
Rheumatoid Arthritis 19 (11.6) 6 9.5 0.515 3 21.4 0.229
*Pearson Chi-square exact 2-sided test
**Other co-morbidities reported, but not listed in the table due to spare data: Atrial fibrillation = 7, Chronic kidney disease = 8, COPD = 8, hypercholesterolemia 
= 13, psychiatric disorders = 10.
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prescribed opioids (Table 2). Results from the amphetamine panel 
showed seven patients tested positive, with four disclosing a history of 
prescribed opioids. For cannabinoids, six were positive, two of which 
disclosed a history of opioids. UDS results for the other drug panel 
showed two positive, with one self-reported opioid prescription. The 
opiate/opioid panel showed 38.6% (64/166) tested positive, but 35 
of 64 patients were using opioids without a prescription (p < 0.01). 
Twenty-eight percent or 35 of 125 with no prescription for opioids 
test positive on UDS. Twenty-nine of 41 with a prescription of opioids 
tested positive on UDS. Thus, it appeared opioid use was significantly 
under-reported prior to surgery.
DISCUSSION
This study suggested that opioid use is relatively common in elderly 
patients who are evaluated for JA surgery in a community-based 
orthopaedic clinic. The results from this study also demonstrated 
that a significantly high portion of these patients have a positive UDS 
for opioids that failed to disclose this information on their initial pre-
operative examination. The prevalence of positive UDS for illicit 
drugs was higher than expected, especially for this relatively elderly 
population. 
This study had limitations. The first limitation was the small popu-
lation size from a single senior author’s clinic with a limited number 
of cases in our study timeframe. The other limitation may come from 
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the relatively narrow detection time of UDS. For instance, oxycodone 
may not be detected if administered more than three days prior to 
testing, according to the Mayo Clinic Laboratories Guidance (https://
www.mayocliniclabs.com/test-info/drug-book/opiates.html). Also, 
this study did not consider the duration and dosage of opioid use, 
which Nguyen et. al.13 has shown to effect clinical outcomes.
However, recent studies such as Ben-Ari et al.3 found that 39.1% 
of patients that underwent a TKA in the U.S. Veterans Affairs (VA) 
system were prescribed long-term opioids pre-operatively; 2.2% of 
these patients required a revision within a year. They concluded that 
long-term opioid use prior to TKA was associated with an increase 
in knee revisions.3 Similarly, Zywiel et al.17 found pre-operative opioid 
use prior to TKA was associated with diminished functional scores, 
increase risk for complications, and prolonged painful recovery. Sing 
et al.15 found an increased correlation between patients on pre-oper-
ative opioids prior to TKA and risk of complications within the first 
90 days post-operatively. They further concluded that pre-operative 
opioid use should be disclosed as a risk for complications to patients 
and should be taken into consideration by the physicians prior to 
opioid management. All these studies justified that pre-operative 
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Table 2. Positive UDS test results for each drug and number of patients with history of prescribed opioids. 
Self-Reported History of Prescribed Opioids
Yes No Total
Positive Urine Drug Screen n = 41 (24.7%) n = 125 (75.3%) n = 166 (100.0%)
Amphetamines Panel 4 9.8 3 2.4 7 4.2
Amphetamine 2 4.9 2 1.6 4 2.4
Phentermine 2 4.9 0 0.0 2 1.2
MDEA 0 0.0 0 0.0 0 0.0
Methamphetamine 0 0.0 2 1.6 2 1.2
Methylphenidate 0 0.0 1 0.8 1 0.6
Cannabinoids Panel 2 4.9 4 3.2 6 3.6
THC 2 4.9 4 3.2 6 3.6
Opiate/Opioid Panel 29 70.7 35 28.0 64 38.6
Oxymorphone 13 31.7 4 3.2 17 10.2
Oxycodone 12 29.3 3 2.4 15 9.0
O-Desmethyl tramadol 10 24.4 14 11.2 24 14.5
Tramadol 10 24.4 14 11.2 24 14.5
Hydrocodone 7 17.1 17 13.6 24 14.5
Hydromorphone 4 9.8 11 8.8 15 9.0
Morphine 3 7.3 1 0.8 4 2.4
Codeine 0 0.0 3 2.4 3 1.8
EDDP 0 0.0 2 1.6 2 1.2
Fentanyl 0 0.0 0 0.0 0 0.0
Methadone 0 0.0 2 1.6 2 1.2
Other Drug Panel 1 2.4 1 0.8 2 1.2
Dextromethorphan 1 2.4 0 0.0 1 0.6
Benzoylecgonine 0 0.0 1 0.8 1 0.6
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opioid use should be screened at the initial examination as part of a 
thorough risk analysis of the patient. Interestingly, these studies only 
looked at the reported prescriptions. The current study may illustrate 
that these patients need to be screened even further because patients 
have access to these medications beyond their current prescriptions. 
Levy et al.27 evaluated the prevalence of illicit drug use in ortho-
paedic trauma patients. They found that patients tested positive for 
alcohol (25%), cocaine (22%), and marijuana (21%).27 They further 
found that patients with a positive screen had more severe ortho-
paedic injuries and longer hospital stays.27 Similarly, Lank et al.26 
also utilized the UDS to evaluate trauma patients over 55 years of 
age and found that patients who tested positive for marijuana and 
cocaine resulted in longer lengths of stay in the ICU compared to 
patients with negative UDS. This is in contrast to the current study, 
which had a more elderly patient population and patients who were 
evaluated for elective cases like JA. Our study found only 3.6% of 
patients tested positive for marijuana. However, this study was not 
performed where marijuana is legal. Furthermore, one could suspect 
that this prevalence would be higher in a state where marijuana has 
been legalized. With this increase in the number of states legalizing 
the use of marijuana, future studies need to evaluate how this will 
affect outcomes in patients who undergo elective orthopaedic cases 
such as JA procedures. 
In this study, all histories of medication intake were clarified with 
the patients when the results of the urine drug screen returned. When 
excluding the patients testing positive for marijuana, 6% of patients 
in this study tested positive for other illicit drugs. This is clinically 
significant especially in a community-based practice such as this 
study was performed. The literature in how illicit drugs effect the out-
comes with orthopaedic procedures is limited, especially in elective 
cases.26,27 However, the ability to evaluate illicit drugs such as cocaine, 
amphetamines, or heroin in elective JA procedures likely is limited 
for future research. It is more realistic for future studies to determine 
how canceling these cases may affect the overall complication rate. 
With recent literature reporting an increase in post-operative 
complications with pre-opioid use,3,14-16 combined with the signifi-
cantly high prevalence of pre-opioid and illicit drug use found in this 
elderly general population and patients not disclosing this informa-
tion on their exam, it may be necessary to utilize the UDS for initial 
risk assessment for patients undergoing JA procedures. However, 
further studies need to evaluate how a positive UDS for pre-operative 
opioids effects patient’s undergoing JA procedures complications 
post-operatively and function outcomes. This study found that access 
to these opioid drugs, other than what patients are prescribed, is 
prominent in the community-based orthopaedic clinic setting and 
further screening needs to be evaluated for pre-operative opioid use. 
Thus, UDS may be clinically helpful in assessing patient’s risks pre-
operatively. 
CONCLUSION
With a significant number of patients testing positive for opioids 
without evidence of a previous prescription, UDS may be beneficial 
for initial risk assessment for patients undergoing JA procedures.
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